Cannabis Technologies Inc. (CANLF) 0.2750 $CANLF
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Cannabis Technologies Announces Second Therapy -- CTI-091
Marketwire - Mon Aug 18, 9:36AM CDT
Cannabis Technologies Inc. (CSE: CAN)(OTCQB: CANLF) is pleased to announce the development of a therapy containing a proprietary mixture of cannabinoids and non-cannabis based active ingredients "CTI-091" for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
Cannabis Technologies Looks to Capitalize on Therapeutics
ACCESSWIRE - Tue Aug 05, 8:36AM CDT
WHITEFISH, MT / August 5, 2014 / The U.S. medical marijuana industry has grown at a 16.2% CAGR between 2009 and 2014 to generate $2 billion in annual revenue, according to IBIS World. With over 1.4 million businesses and a growing number of public companies in the space, investors have a number of options when looking to gain exposure, ranging from large firms running clinical trials to small firms developing delivery systems.
If Big Pharma Isn't Nervous, It Should Be
ACCESSWIRE - Thu Jul 31, 9:54AM CDT
Early Stage Cannabis Technologies...Potentially The Next GW Pharma
If Big Pharma Isn't Nervous, It Should Be; Early Stage Cannabis Technologies...Potentially the Next GW Pharma
GlobeNewswire - Thu Jul 31, 9:10AM CDT
Deep in the brain, buried within the central nervous system as well as lymphatic tissues and organs throughout the body are cannabinoid receptors; patiently waiting to help address a myriad of diseases. With the advent of cannabis research and therapy development many patients will likely trigger them very soon.
Cannabis Stocks Moved Lower Last Week, but Novus & Terra Tech Were Smokin'
ACCESSWIRE - Mon Jul 28, 8:33AM CDT
WHITEFISH, MT / July 28, 2014 / The Marijuana Index(TM) moved lower last week after a modest 1.6% rise in bellwether GW Pharmaceuticals plc (NASDAQ: GWPH) was offset by a significant 4.9% drop in MedBox Inc. (OTC: MDBX) shares.
Advocate Cheryl Shuman Discusses CBD Benefits and Cannabis Technologies on CTV Interview
ACCESSWIRE - Tue Jul 22, 11:05AM CDT
Whitefish, MT / July 22, 2014 / Cannabis Technologies Inc. (OTC:CANLF), a leading innovator of technology and science within the cannabis sector, was recently highlighted in a Canadian TV ("CTV"
interview discussing the benefits of medical marijuana. As an ovarian cancer survivor, Ms. Shuman has become a leading advocate for the ongoing legalization of cannabis and research conducted by companies in the space, particularly companies like Cannabis Technologies that are working to reduce the time to commercialize cannabis based therapies.
Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Cannabis Technologies: A "Junior GW" Play on Cannabinoid's Potential
ACCESSWIRE - Wed Jun 25, 8:27AM CDT
WHITEFISH, MT / June 25, 2014 / Cannabinoids are a diverse set of chemical compounds that act on cannabinoid receptors on cells that repress neurotransmitter release in the brain. While tetrahydrocannabinol ("THC" and cannabidiol ("CBD" are the two most popular cannabinoids, there are at least 85 different cannabinoids isolated from cannabis exhibiting various effects that could prove therapeutic.
Cannabis Technologies Announces Glaucoma Therapy Entering Into Phase 1 Clinical Trials
Marketwire - Tue Jun 24, 5:01AM CDT
Cannabis Technologies Inc. (CSE: CAN)(OTCQB: CANLF) is pleased to announce its first therapy, CT1-085, which is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma.
A New Cannabinoid-based Arthritis Therapy in the Making
ACCESSWIRE - Tue Aug 19, 8:50AM CDT
WHITEFISH, MT / August 19, 2014 / Cannabinoids have been the focus of intense clinical research following the legalization of medical cannabis by several U.S. states. While pioneers like British-based GW Pharmaceuticals plc (NASDAQ: GWPH) have been actively studying cannabinoids since the 1990s, many North American companies haven't started major research until recent years with compounds just starting clinical trials.
Cannabis Technologies Announces Second Therapy -- CTI-091
Marketwire - Mon Aug 18, 9:36AM CDT
Cannabis Technologies Inc. (CSE: CAN)(OTCQB: CANLF) is pleased to announce the development of a therapy containing a proprietary mixture of cannabinoids and non-cannabis based active ingredients "CTI-091" for the relief of joint pain and swelling associated with arthritis and joint disease. Preliminary laboratory studies showed CTI-091 suppresses the human macrophage interleukin-6, a major biomarker of inflammation, indicating strong scientific evidence that cannabis extracts reverse the disease progression.
Vape Holdings & Terra Tech Were Top Cannabis Stock Gainers Last Week
ACCESSWIRE - Tue Aug 12, 8:47AM CDT
WHITEFISH, MT / August 12, 2014 / The Marijuana Index(TM) moved lower last week, as bellwethers GW Pharmaceuticals plc (NASDAQ: GWPH) and MedBox Inc. (OTC: MDBX) fell 0.8% and 14%, respectively, alongside many other smaller industry components.
Cannabis Technologies Looks to Capitalize on Therapeutics
ACCESSWIRE - Tue Aug 05, 8:36AM CDT
WHITEFISH, MT / August 5, 2014 / The U.S. medical marijuana industry has grown at a 16.2% CAGR between 2009 and 2014 to generate $2 billion in annual revenue, according to IBIS World. With over 1.4 million businesses and a growing number of public companies in the space, investors have a number of options when looking to gain exposure, ranging from large firms running clinical trials to small firms developing delivery systems.
If Big Pharma Isn't Nervous, It Should Be
ACCESSWIRE - Thu Jul 31, 9:54AM CDT
Early Stage Cannabis Technologies...Potentially The Next GW Pharma
If Big Pharma Isn't Nervous, It Should Be; Early Stage Cannabis Technologies...Potentially the Next GW Pharma
GlobeNewswire - Thu Jul 31, 9:10AM CDT
Deep in the brain, buried within the central nervous system as well as lymphatic tissues and organs throughout the body are cannabinoid receptors; patiently waiting to help address a myriad of diseases. With the advent of cannabis research and therapy development many patients will likely trigger them very soon.
Cannabis Stocks Moved Lower Last Week, but Novus & Terra Tech Were Smokin'
ACCESSWIRE - Mon Jul 28, 8:33AM CDT
WHITEFISH, MT / July 28, 2014 / The Marijuana Index(TM) moved lower last week after a modest 1.6% rise in bellwether GW Pharmaceuticals plc (NASDAQ: GWPH) was offset by a significant 4.9% drop in MedBox Inc. (OTC: MDBX) shares.
Advocate Cheryl Shuman Discusses CBD Benefits and Cannabis Technologies on CTV Interview
ACCESSWIRE - Tue Jul 22, 11:05AM CDT
Whitefish, MT / July 22, 2014 / Cannabis Technologies Inc. (OTC:CANLF), a leading innovator of technology and science within the cannabis sector, was recently highlighted in a Canadian TV ("CTV"
interview discussing the benefits of medical marijuana. As an ovarian cancer survivor, Ms. Shuman has become a leading advocate for the ongoing legalization of cannabis and research conducted by companies in the space, particularly companies like Cannabis Technologies that are working to reduce the time to commercialize cannabis based therapies. Marijuana Sector Positioned to Move Higher as FDA Reviews Drug's Status
ACCESSWIRE - Mon Jun 30, 8:32AM CDT
WHITEFISH, MT / June 30, 2014 / The Marijuana Index(TM) traded marginally lower last week after MedBox Inc. (OTC: MDBX) and CannaVEST Corp.'s (OTC: CANV) moves lower offset GW Pharmaceuticals plc's (NASDAQ: GWPH) modest gains.
Cannabis Technologies: A "Junior GW" Play on Cannabinoid's Potential
ACCESSWIRE - Wed Jun 25, 8:27AM CDT
WHITEFISH, MT / June 25, 2014 / Cannabinoids are a diverse set of chemical compounds that act on cannabinoid receptors on cells that repress neurotransmitter release in the brain. While tetrahydrocannabinol ("THC"
and cannabidiol ("CBD" are the two most popular cannabinoids, there are at least 85 different cannabinoids isolated from cannabis exhibiting various effects that could prove therapeutic. Cannabis Technologies Announces Glaucoma Therapy Entering Into Phase 1 Clinical Trials
Marketwire - Tue Jun 24, 5:01AM CDT
Cannabis Technologies Inc. (CSE: CAN)(OTCQB: CANLF) is pleased to announce its first therapy, CT1-085, which is a topical formulation containing a proprietary compound of cannabinoids and non-cannabis based active ingredients for the treatment of Glaucoma.
